Antiproliferative, differentiating and apoptotic effects elicited by Imidazo[1,2-a]pyrazine derivatives

General Pharmacology

Volumn 32, Issue 1, 1999, Pages 135-141

  Zurbonsen, K ^a   Michel, A ^b   Bonnet, P A ^c   Mathieu, M N ^a   Chevillard, C ^a  

^a INSERM   (France)

^b Lab Pharmacologie   (France)

^c Laboratoire de Chimie Organique   (France)

Author keywords

Apoptosis; cAMP; cGMP; Differentiation; Imidazo 1,2 a pyrazine derivatives; Phospho diesterases; Proliferation; Purinoceptors

Indexed keywords

3 BROMO 8 METHYLAMINOIMIDAZO[1,2 A]PYRAZINE; 6 BROMO 8 METHYLAMINOIMIDAZO[1,2 A]PYRAZINE; 6 BROMO 8 METHYLAMINOIMIDAZO[1,2 A]PYRAZINE 2 CARBONITRILE; CYCLIC AMP PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; DNA; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; IMIDAZOPYRAZINE DERIVATIVE; ISOBUTYLMETHYLXANTHINE; MILRINONE; PHOSPHODIESTERASE; PURINE RECEPTOR; ROLIPRAM; SC 18; SC 51; SCA 41; SCA 44; UNCLASSIFIED DRUG; ZAPRINAST;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIPOPHILICITY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHOSPHODIESTERASE INHIBITORS; PYRAZINES; RECEPTORS, PURINERGIC;

EID: 0032889832     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00097-4     Document Type: Review

References (31)

1. Aharoni D., Dantes A., Oren M., Amsterdam A. cAMP-mediated signals as determinants for apoptosis in primary granulosa cells. Exp. Cell Res. 218:1995;271-276.
2. Bang B.E., Ericsen C., Aarbakke J. Effects of cAMP and cGMP elevating agents on HL-60 cell differentiation. Pharmacol. Toxicol. 75:1994;108-112.
3. Banner K.H., Page C.P. Effect of type III and IV isoenzyme selective phosphodiesterase (PDE) inhibitors on proliferation of human peripheral blood mononuclear cells. Br. J. Pharmacol. 113:1994;89P.
4. Bonnet P.A., Michel A., Laurent F., Sablayrolles C., Rechencq E., Mani J.C., Boucard M., Chapat J.P. Synthesis and antibronchospastic activity of 8-alkoxy- and 8-(alkylamino)imidazo[1,2-a]-pyrazine. J. Med. Chem. 35:1992;3353-3358.
5. Boss G.R. cGMP-induced differentiation of the promyelocytic cell-line HL-60. Proc. Natl. Acad. Sci. USA. 86:1989;7174-7178.
6. Chaplinski T.J., Niedel J.E. Cyclic nucleotide-induced maturation of human promyelocytic leukemia cells. J. Clin. Invest. 70:1982;953-964.
7. Cho-Chung Y.S. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy. new approches to therapy Cancer Res. 50:1990;7093-7100.
8. Cook S.J., Archer K., Martin A., Buchheit K.H., Fozard J.R., Müller T., Miller A.J., Elliot K.R.F., Foster R.W., Small R.C. Further analysis of the mechanisms underlying the tracheal relaxant action of SCA40. Br. J. Pharmacol. 114:1995;143.
9. Dress M., Zimmermann R., Eisenbrand G. 3′,5′-cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res. 53:1993;3058-3061.
10. Greenberg S.M., Rosenthal D.S., Greeley T.A., Tantravahi R., Handin R. Characterization of a new megakaryocytic cell line. The Dami cell Blood. 72:1988;1968-1977.
11. Jonzon B., Nilsson J., Fredholm B.B. Adenosine receptor-mediated changes in cyclic AMP production and DNA synthesis in cultured arterial smooth muscle cells. J. Cell Physiol. 124:1985;451-456.
12. Laurent F., Pocock T., Elliot K.R.F., Portet K., Benezech V., Vitse O. Relaxant and phosphodiesterase inhibition activities of imidazo [1,2-a]pyrazine derivatives. Fundam. Clin. Pharmacol. 10:1996;65.
13. Levallois C., Bonnafous J.C., Françoise M.A., Sablayrolles C., Chapat J.P., Mani J.C. Theophylline-like properties of xanthine analogs. Biochem. Pharmacol. 33:1984;2253-2257.
14. Marcoz P., Prigent A.F., Lagarde M., Nemoz G. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol. Pharmacol. 44:1993;1027-1035.
15. Michel A., Laurent F., Chapat J.P., Boucard M., Bonnet P.A. Pharmacological activities of imidazo[1,2-a]pyrazine derivatives. Arzneimittelforschung. 45:1995;1288-1293.
16. Pan X., Arauz E., Krzanowski J.J., Fitzpatrick D.F., Polson J.B. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem. Pharmacol. 48:1994;827-835.
17. Pocock T.M., Small R.C. Studies of the effects of SCA40 in relaxing bovine trachealis muscle and in inhibiting isoenzymes of cyclic nucleotide phosphodiesterase. Br. J. Pharmacol. 117:1996;209.
18. Rathbone M.P., Deforge S., Deluca B., Gabel B., Laurenssen C., Middlemiss P., Parkinson S. Purinergic stimulation of cell division and differentiation. Mechanisms and pharmacological implications Med. Hypotheses. 37:1992;213-219. a.
19. Sablayrolles C., Cros G.H., Milhavet J.C., Rechenq E., Chapat J.P., Boucard M., Serrano J.J., McNeil J.H. Synthesis of imidazo[1,2-a]pyrazine derivatives with uterine relaxing antibronchospastic, and cardiac-stimulating properties. J. Med. Chem. 27:1984;206-212.
20. 3H]2-MeS-ADP on megakaryocytoblastic cell lines in culture. Biochem. Pharmacol. 48:1994;83-86.
21. Smets L.A. Programmed cell death (apoptosis) and response to anti-cancer drugs. Anticancer Drugs. 5:1994;3-9.
22. Souness J.E., Hassall G.A., Parrott D.P. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 44:1992;857-866.
23. Takahashi S., Oida K., Fujiwara R., Maeda H., Hayashi S., Takai H., Tamai T., Nakai T., Miyabo S. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J. Cardiovasc. Pharmacol. 20:1992;900-906.
24. Tanaka Y., Yoshihara K., Tsuyuki M., Kamiya T. Apoptosis induced by adenosine in human leukemic HL-60 cells. Exp. Cell Res. 213:1994;242-247.
25. Tey H.B., Khoo H.E., Tan C.H. Adenosine modulates cell growth in human epidermoid carcinoma (A431)cells. Biochem. Biophys. Res. Commun. 187:1992;1486-1492.
26. Vittet D., Duperray C., Chevillard C. Cyclic-AMP inhibits cell growth and negatively interacts with platelet membrane glycoprotein expression on the Dami human megakaryoblastic cell line. J. Cell Physiol. 163:1995;645-655.
27. Zurbonsen K., Chevillard C., Vittet D., Bonnet P.A., Michel A. Inhibition of human erythroleukemia (HEL) cell proliferation by imidazo[1,2-a]pyrazine derivatives. Fundam. Clin. Pharmacol. 8:1994;260.
28. Zurbonsen K., Michel A., Vittet D., Bonnet P.A., Gannoun-Zaki L., Mathieu M.N., Chevillard C. Apoptotic effects of imidazo[1,2-a]pyrazine derivatives in human Dami cell line. Eur. J. Pharmacol. 20:1997;215-221. a.
29. Zurbonsen K., Michel A., Vittet D., Bonnet P.A., Chevillard C. Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on Dami cell line. Biochem. Pharmacol. 53:1997;1141-1147. b.
30. Zurbonsen K., Michel A., Vittet D., Bonnet P.A., Chevillard C. Antiproliferative effects of imidazo[1,2-a]pyrazine on the Dami cell line. Biochem. Pharmacol. 54:1997;365-371. c.
31. Zurbonsen K., Michel A., Vittet D., Bonnet P.A., Chevillard C. Modulation of the megakaryoblastic Dami cell line differentiation by phosphodiesterase inhibitors and imidazo[1,2-a]pyrazine derivatives. Pharmacol. Toxicol. 80:1997;286-289. d.